DXS INTERNATIONAL PLC
Notification of Director / PDMR Dealing
The Board of DXS International plc (the “Company”), the AQSE Growth Market quoted clinical decision support developer and supplier of clinical decision support systems confirms that the Placing Shares and the Stakeholder Shares referred to in the Announcement of 17th May have this morning been admitted to trading on the Aquis Stock Exchange.
As part of the Placing and Conversion of Debt DL Services Limited, (a company owned and controlled by the Chief Executive’s wife), has been issued with 753,244 Ordinary Shares in the Company at the Placing Price of 4p per share.
Following the transaction specified above Mr Immelman’s interests, including those of persons closely associated with him, is 6,523,829 Ordinary Shares representing 10.19% of the issued share capital of the Company.
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||||
| a) | Name | DL Services Limited | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | a company owned and controlled by the Chief Executive’s wife | |||
| b) | Initial notification /Amendment | Initial | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | DXS INTERNATIONAL PLC | |||
| b) | LEI | 2138001R1KEUWTXEVJ44 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial instrument, type of instrument | Ordinary Shares of 0.33p each | |||
| Identification code | ISIN GB00B2Q6HZ92 | ||||
| b) | Nature of the transaction | Subscription | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| 4p | 753,244 | ||||
| d) | Aggregated information | ||||
| - Aggregated volume | |||||
| - Price | |||||
| e) | Date of the transaction | 24 May 2023 | |||
| f) | Place of the transaction | Off market | |||
The Directors of DXS International plc accept responsibility for this announcement
Enquiries:
| David Immelman (Chief Executive) DXS International plc | 01252 719800 david@dxs-systems.com |
| Wrecclesham House Wrecclesham Road Farnham Surrey GU10 4PS | |
| www.dxs-systems.co.uk |
| Corporate Advisor | |
| David Papworth City & Merchant | 0207 101 7676 |
| Corporate Broker | |
| Hybridan LLP Claire Louise Noyce | 020 3764 2341 |
Note to Editors:
DXS International presents up to date treatment guidelines and recommendations, from Clinical Commissioning Groups and other trusted NHS sources, to doctors, nurses and pharmacists in their workflow and during the patient consultation. This effective clinical decision support ultimately translates to improved healthcare outcomes delivered more cost effectively which should significantly contribute towards the NHS achieving its projected efficiency savings.
